Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
Kelderman, S Heemskerk, B van Tinteren, H van den Brom, R Hospers, G van den Eertwegh, A Kapiteijn, E de Groot, J Soetekouw, P Jansen, R
Kelderman, S
Heemskerk, B
van Tinteren, H
van den Brom, R
Hospers, G
van den Eertwegh, A
Kapiteijn, E
de Groot, J
Soetekouw, P
Jansen, R
Citations
Altmetric:
Abstract
Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved overall survival (OS) in metastatic melanoma in phase III trials. However, about 80 % of patients fail to respond, and no predictive markers for benefit from therapy have been identified. We analysed a 'real world' population of patients treated with ipilimumab to identify markers for treatment benefit.
Description
Date
2014-05
Publisher
Collections
Keywords
Type
Article
Citation
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. 2014, 63 (5):449-58 Cancer Immunol Immunother